Real-world data confirms that the favorable safety profile of CAR T-cell therapies like Obicell holds true in broad clinical practice. This has been a crucial factor in expanding eligibility to older patients, with successful treatments now being administered to individuals in their 70s and 80s.

Moving CAR T-cell therapy to earlier treatment lines is crucial. This approach targets cancer before it develops resistance and, more importantly, utilizes patient T-cells that are healthier and more effective, not having been damaged by extensive prior chemotherapy regimens.

Unlike stem cell transplants, CAR T-cell therapy has less intense conditioning, making it a viable option for patients into their late 80s. Eligibility focuses more on fitness and frailty rather than chronological age, broadening access for a larger patient population.

An investigational in vivo CAR-T therapy uses viral particles infused directly into the patient to convert their T-cells into CAR-T cells. This approach eliminates the complex steps of apheresis, lymphodepletion, and ex vivo manufacturing, effectively creating an off-the-shelf product that becomes an autologous treatment inside the body.

It's a myth that patients must have active disease to receive their manufactured CAR-T cells. Data from the TRANSFORM study shows that patients who achieved a complete response with bridging therapy while awaiting cell manufacturing still proceeded with the infusion and benefited.

The argument against using certain frontline therapies for fear of compromising future CAR-T eligibility is tempered by a stark reality: only 5% of eligible US patients actually receive CAR-T. This logistical and access bottleneck means that optimizing immediate, available treatments is paramount for the vast majority of patients.

Experts report successfully treating lymphoma patients as old as 92 with CAR-T, even those with mild cognitive impairment. This demonstrates that chronological age alone is not an absolute contraindication; functional status is a more critical determinant of eligibility for intensive therapies.

Without head-to-head trials, clinicians select between Obicell and Brexacel based on a practical algorithm. Patient factors like age and frailty, disease burden, and logistical concerns like product availability dictate the selection, with safer options prioritized for high-risk patients.

Experts vehemently state that patients ineligible for autologous stem cell transplant are not necessarily ineligible for CAR-T therapy. This corrects a critical misconception, urging community oncologists to refer these patients for CAR-T evaluation as they may still be candidates.